These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2317609)

  • 1. Acipimox and hypertriglyceridaemia.
    Bain SC; Jones AF; Barnett AH
    Br J Hosp Med; 1990 Mar; 43(3):182. PubMed ID: 2317609
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment possibility of hypercholesterolaemia associated with hypertriglyceridaemia.
    Paragh G; Balogh Z; Boda J; Kovács P; Kárpáti L; Szabó J; Leövey A
    Acta Biol Hung; 1997; 48(3):359-67. PubMed ID: 9406614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Acipimox (Olbetam) as a secondary hypolipemic agent in combined hypertriglyceridemia and hyperlipidemia].
    Yeshurun D; Hamood H; Morad N; Naschitz J
    Harefuah; 2000 Apr; 138(8):650-3, 710. PubMed ID: 10883206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of acipimox on diabetes mellitus-associated hyperlipoproteinemia].
    Paragh G; Balogh Z; Boda J; Mohácsi A; Juhász A; Leövey A
    Orv Hetil; 1993 Jan; 134(3):121-4. PubMed ID: 8421622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bezafibrate and serum amyloid A--low-density lipoprotein complex in patients with type 2 diabetes mellitus and hypertriglyceridemia.
    Kotani K; Satoh N; Yamada T
    Eur J Intern Med; 2010 Apr; 21(2):e10. PubMed ID: 20206863
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy and clinical trials.
    Usman M; Peter R
    Curr Opin Lipidol; 2006 Oct; 17(5):612-4. PubMed ID: 16960511
    [No Abstract]   [Full Text] [Related]  

  • 7. [Personal experience with the hypolipidemic agent Olbetam-Acipimox in hyperlipoproteinemia associated with type II diabetes].
    Rajecová E; Kréze A; Klimes I; Cvrkalová A; Lacko A; Langrová H; Hanzen E
    Cas Lek Cesk; 1991 Nov; 130(22-23):661-3. PubMed ID: 1786587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid disorders in type 1 and type 2 diabetes.
    Goldberg RB; Capuzzi D
    Clin Lab Med; 2001 Mar; 21(1):147-72, vii. PubMed ID: 11321932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment.
    Vaverkova H; Frohlich J; Jackuliakova D; Novotny D
    Clin Biochem; 2005 Jun; 38(6):509-13. PubMed ID: 15885228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninsulin dependent diabetes mellitus: the importance of dyslipidaemia.
    Scott RS; Florkowski CM
    N Z Med J; 1994 Apr; 107(976):155-6. PubMed ID: 8164903
    [No Abstract]   [Full Text] [Related]  

  • 11. Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients.
    Chan WB; Tong PC; Chow CC; So WY; Ng MC; Ma RC; Osaki R; Cockram CS; Chan JC
    Diabetes Metab Res Rev; 2005; 21(2):183-8. PubMed ID: 15386811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of acipimox and pravastatin in patients with combined hyperlipidemia.
    Fogari R; Marasi G; Vanasia A; Zoppi A; Lusardi P; Preti P
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):61-4. PubMed ID: 9147709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acipimox--a nicotinic acid analogue for hyperlipidaemia.
    Drug Ther Bull; 1991 Jul; 29(15):57-9. PubMed ID: 1914867
    [No Abstract]   [Full Text] [Related]  

  • 14. [Treatment of dyslipidemias and its benefits].
    Taskinen MR
    Duodecim; 1999; 115(10):1138-44. PubMed ID: 11877853
    [No Abstract]   [Full Text] [Related]  

  • 15. [Dyslipoproteinemia of diabetes: fibrates or statins?].
    Moulin P
    Diabetes Metab; 1999 Sep; 25(3):270-4. PubMed ID: 10499198
    [No Abstract]   [Full Text] [Related]  

  • 16. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1998 May; 243(5):151-6. PubMed ID: 9651568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
    Hoogerbrugge N; Jansen H; De Heide L; Zillikens MC; Deckers JW; Birkenhäger JC
    J Intern Med; 1997 Feb; 241(2):151-5. PubMed ID: 9077372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)].
    Quintão EC; de Castilho LN
    Arq Bras Cardiol; 1985 Jan; 44(1):37-40. PubMed ID: 4062591
    [No Abstract]   [Full Text] [Related]  

  • 19. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
    Sheu WH; Jeng CY; Lee WJ; Lin SY; Pei D; Chen YT
    Metabolism; 2001 Mar; 50(3):355-9. PubMed ID: 11230791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood and plasma viscosity after acipimox treatment in hypertriglyceridemic patients.
    Montefusco S; Iannaci G; Gnasso A; Cortese C; Lamenza F; Postiglione A
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):492-4. PubMed ID: 3235215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.